

Stock code: 301035

Stock abbreviation: Rainbow Agro

Announcement No.: 2025-

061

SHANDONG WEIFANG RAINBOW CHEMICAL CO., LTD

The Third Quarter Financial Report of 2025

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate, and complete, without false records, misleading statements, or material omissions.

1. Consolidated balance sheet

Prepared by: Shandong Weifang Rainbow Chemical Co., Ltd

September 30, 2025

Unit: RMB

Item	Closing balance	Opening balance
Current assets:		
Monetary funds	4,339,962,435.07	3,127,278,835.99
Deposit reservation for balance		
Lending to banks and other financial institutions		
Financial assets held for trading	13,883,443.27	
Derivative financial assets	36,111,171.49	54,510,264.04
Notes receivable	10,399,309.87	1,549,052.97
Accounts receivable	5,311,193,073.43	5,383,557,983.75
Receivables financing	3,939,593.14	1,781,600.00
Pre-payments	109,444,371.28	73,111,436.20
Premium receivable		
Re-insurance accounts receivable		
Reserves for re-insurance contract receivable		
Other receivables	73,053,224.74	44,619,050.70
Including: interest receivable		
Dividends receivable		
Financial assets purchased		

under resale agreement		
Inventory	3,017,477,181.86	2,417,727,613.29
Including: Data resources		
Contracted assets		
Assets held for sale		
Non-current assets that mature within one year		
Other current assets	466,125,430.26	373,525,517.33
Total current assets	13,381,589,234.41	11,477,661,354.27
Non-current assets:		
Disbursed loans and advances		
Debt investments		
Other debt investment		
Long-term receivables		
Long-term equity investment	937,915.06	1,163,628.51
Other equity instrument investment		
Other non-current financial assets		
Investment real estate	7,419,943.05	7,888,049.83
Fixed assets	2,487,255,618.25	2,329,749,377.60
Construction in progress	496,009,902.73	380,857,052.90
Productive biological assets		
Oil and gas assets		
Assets with rights of use	35,120,238.91	40,483,198.54
Intangible assets	347,064,146.99	289,263,633.21
Including: Data resources		
Development expenditure	336,930,816.60	209,479,407.05
Including: Data resources		
Goodwill	89,560,239.36	89,560,239.36
Long-term deferred expenses	26,465,331.27	30,010,596.27
Deferred income tax assets	290,285,433.24	351,419,889.32
Other non-current assets	66,846,911.93	88,284,699.67
Total non-current assets	4,183,896,497.39	3,818,159,772.26
Total assets	17,565,485,731.80	15,295,821,126.53
Current liabilities:		
Short-term loan	2,191,394,296.84	2,499,413,865.13
Borrowings from the central bank		
Borrowing from banks and financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities	117,422,066.69	8,956,113.54

Notes payable	4,556,241,988.49	3,498,164,564.46
Accounts payable	1,561,191,016.35	1,054,785,779.66
Advance receipts		222,816.73
Contract liability	108,186,713.41	105,244,393.90
Financial assets sold for repurchase		
Deposits and interbank deposits received		
Amount received from agency trading of securities		
Amount received from agency underwriting of securities		
Payroll payable	273,003,879.64	254,619,742.83
Taxes payable	215,563,137.32	133,155,202.22
Other payables	142,995,748.02	145,690,804.57
Including: Interests payable		
Dividends payable		4,531,016.11
Charges and commissions payable		
Re-insurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	238,031,085.82	63,599,585.20
Other current liabilities	9,338,111.03	5,682,444.72
Total current liabilities	9,413,368,043.61	7,769,535,312.96
Non-current liabilities:		
Provision for insurance contracts		
Long-term loan	282,100,000.00	345,772,094.74
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liability	26,815,215.80	31,665,904.44
Long-term payables		
Long-term payroll payable		
Accrued liabilities		
Deferred income	18,828,408.95	13,105,155.44
Deferred income tax liabilities	66,007,511.24	86,672,265.19
Other non-current liabilities		
Total non-current liabilities	393,751,135.99	477,215,419.81
Total liabilities	9,807,119,179.60	8,246,750,732.77
Owner's equity:		
Share capital	280,770,974.00	280,770,974.00
Other equity instruments		
Including: Preferred shares		

Perpetual bonds		
Capital reserve	2,464,548,672.39	2,442,307,122.42
Less: Treasury stock	124,837,079.67	124,837,079.67
Other comprehensive income	-62,995,026.27	-5,194,711.56
Special reserve	46,837,027.58	46,616,455.84
Surplus reserve	158,674,657.07	158,674,657.07
General risk reserve		
Undistributed profit	4,540,593,714.68	3,862,347,597.59
Total owners' equity attributed to parent company	7,303,592,939.78	6,660,685,015.69
Minority shareholder's interest	454,773,612.42	388,385,378.07
Total owner's equity	7,758,366,552.20	7,049,070,393.76
Total liabilities and owners equity	17,565,485,731.80	15,295,821,126.53

Legal Representative:

Chief Accountant in Charge:

Chief of Accounting

Institution:

Wicky Wang

Xing Bingpeng

Zhang Baolin

2. Consolidated income statement from the start of 2025 to the end of Q3 2025

Unit: RMB

Item	Amount incurred in Q3 2025	Amount incurred in Q3 2024
I. Gross Operating Income	10,911,452,781.83	9,785,195,972.58
Including: Operating income	10,911,452,781.83	9,785,195,972.58
Interest income		
Premium earned		
Handling charges and commissions income		
II. Total Operating Costs	9,410,987,950.18	9,252,287,316.15
Including: Costs of business	8,501,898,847.49	7,792,500,818.76
Interest expenses		
Handling charges and commission expenses		
Surrender value		
Net payments for insurance claims		
Net withdrawal of reserve for insurance responsibility contracts		
Expenditures of policy dividend		
Re-insurance expense		
Taxes and surcharges	49,558,778.47	39,814,479.82
Sales expenses	541,276,149.24	423,513,169.91

Management expenses	401,415,429.92	347,669,755.50
R&D expenditures	133,772,534.32	125,724,753.40
Financial expenses	-216,933,789.26	523,064,338.76
Including: Interest expenses	75,022,595.81	99,487,677.45
Interest income	32,405,171.62	43,940,586.89
Add: Other incomes	4,654,362.94	3,991,872.23
Income from investment ("-" for loss)	-16,249,258.28	49,165,040.33
Including: Income from investment in associated enterprises and joint ventures	-225,713.45	-328,142.06
Income recognized at termination of financial assets measured at amortized cost		
Foreign exchange gain ("-" for loss)		
Net exposure hedging income ("-" for loss)		
Income from changes in fair value ("-" for loss)	-128,100,023.82	2,019,179.28
Credit impairment losses ("-" for loss)	-114,676,622.01	-54,849,016.88
Asset impairment losses ("-" for loss)	-2,428,761.50	-2,669,069.36
Gains from asset disposal ("-" for loss)	165,266.75	372,584.56
III. Operating profit ("-" for loss)	1,243,829,795.73	530,939,246.59
Add: Non-operating income	5,315,310.98	5,516,285.50
Less: Non-operating expenses	17,152,244.50	11,676,646.36
IV. Total profit ("-" for total loss)	1,231,992,862.21	524,778,885.73
Less: Income tax expenses	234,569,908.14	124,761,602.87
V. Net profit ("-" for net loss)	997,422,954.07	400,017,282.86
(I) Classification by business continuity		
1. Net profit from continuing operations ("-" for net loss)	997,422,954.07	400,017,282.86
2. Net profit from discontinued operations ("-" for net loss)		
(II) Classification by ownership		
1. Net profit attributable to shareholders of the parent company ("-" for net loss)	889,733,619.13	341,563,969.19
2. Profit and loss of minority shareholders ("-" for net loss)	107,689,334.94	58,453,313.67
VI. Net amount after tax of other comprehensive income	-57,800,314.71	-42,550,846.46
Net amount of other comprehensive income after tax	-57,800,314.71	-42,550,846.46

attributed to the owners of parent company		
(I) Other comprehensive income that cannot be reclassified into profit or loss		
1. Changes due to re-measurement on defined benefit plan		
2. Other comprehensive income that cannot be converted into profit and loss under the equity method		
3. Changes in fair value of other equity instrument investments		
4. Changes in the fair value of the credit risk of the enterprise		
5. Other		
(ii) Other comprehensive income that will be reclassified into profit and loss	-57,800,314.71	-42,550,846.46
1. Other comprehensive income that can be converted to profit or loss under the equity method		
2. Changes in fair value for other investment on bonds		
3. Amount of financial assets reclassified into other comprehensive income		
4. Provision for credit impairment of other creditor's rights investment		
5. Cash flow hedge reserve		
6. Difference of foreign currency financial statement translation	-57,800,314.71	-42,550,846.46
7. Other		
Net amount of other comprehensive income after tax attributed to minority shareholders		
VII. Total comprehensive income	939,622,639.36	357,466,436.40
(i) Total comprehensive income attributed to parent company owners	831,933,304.42	299,013,122.73
(ii) Total comprehensive income attributed to minority shareholders	107,689,334.94	58,453,313.67
VIII. Earnings per Share:		
(i) Basic earnings per share	3.20	1.23
(ii) Diluted earnings per share	3.18	1.22

Legal Representative:

Chief Accountant in Charge:

Chief of Accounting

Institution:

Wicky Wang

Xing Bingpeng

Zhang Baolin

3. Consolidated cash flow statement from the start of 2025 to the end of Q3 2025

Unit: RMB

Item	Amount incurred in Q3 2025	Amount incurred in Q3 2024
I. Cash Flows Generated from Operating Activities:		
Cash received from sales of goods and services	10,927,180,152.79	9,785,676,523.98
Net increase in deposit from customers and interbank		
Net increase in borrowing from central bank		
Net increase in borrowings from other financial institutions		
Cash receipts from premiums under direct insurance contracts		
Net cash receipts from re-insurance business		
Net cash receipts from policyholders' deposits and investments		
Cash receipts from interest, handling fees and commissions		
Net increase in capital borrowed from banks and other financial institutions		
Net increase in repurchase business capital		
Net cash received from securities trading brokerage		
Cash receipts from tax refunds	682,472,830.95	559,950,192.80
Cash received relating to other operating activities	45,534,591.11	53,448,744.62
Subtotal of cash inflow in business activities	11,655,187,574.85	10,399,075,461.40
Cash payments for goods acquired and services received	8,193,069,943.45	8,690,179,604.53
Net increase in customer loans and advances		
Net increase in deposits in central bank and interbank		
Cash payments for original insurance contract claims		
Net increase in lending funds from banks and other financial institutions		

Cash payments for interest, fee and commission		
Cash payments for insurance policyholder dividends		
Cash payments to employees and on behalf of employees	749,380,596.43	649,126,850.71
Cash payments for taxes	234,736,883.10	174,285,039.83
Other cash payments relating to operating activities	737,685,814.09	426,402,544.95
Subtotal of cash outflow in business activities	9,914,873,237.07	9,939,994,040.02
Net cash flow from operating activities	1,740,314,337.78	459,081,421.38
II. Cash Flows from Investing Activities:		
Cash receipts from investment withdrawal		
Cash receipts from return on investments		
Net cash receipts from disposals of fixed assets, intangible assets and other long-term assets		10,964,665.77
Net cash receipts from disposal of subsidiary or any other business unit		
Other cash receipts relating to investing activities	15,056,546.36	49,560,659.67
Subtotal of cash inflow in investment activities	15,056,546.36	60,525,325.44
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	551,490,687.04	441,397,785.79
Cash payments for investment		
Net increase in pledged loans		
Net cash payments to acquire subsidiary and other business units		
Other cash payments relating to investment activities	32,427,588.54	
Subtotal of cash outflow in investment activities	583,918,275.58	441,397,785.79
Net cash flow in investment activities	-568,861,729.22	-380,872,460.35
III. Cash Flows from Financing Activities:		
Cash received from capital contributions		
Including: Cash received from		

investment of minority shareholder from subsidiary		
Cash receipts from borrowings	1,857,928,465.40	4,086,885,629.73
Other cash receipts relating to financing activities		
Subtotal of cash inflow in financing activities	1,857,928,465.40	4,086,885,629.73
Cash repayments of borrowings	2,143,533,066.02	3,112,746,706.74
Cash payments for distribution of dividends, profits, or cash payments for interest expenses	303,857,067.85	396,722,978.21
Including: Dividends and profits paid to minority shareholders by subsidiaries		
Other cash paid related to financing activities		
Subtotal of cash outflow in financing activities	2,447,390,133.87	3,509,469,684.95
Net cash flow from financing activities	-589,461,668.47	577,415,944.78
IV. Effect of Exchange Rate Changes on Cash and Cash Equivalents	40,593,995.74	98,278,584.55
V. Net Increase in Cash and Cash Equivalents	622,584,935.83	753,903,490.36
Add: Beginning balance of cash and cash equivalents	1,288,636,135.42	1,185,554,395.09
VI. Closing Balance of Cash and Cash Equivalents	1,911,221,071.25	1,939,457,885.45

In case of any discrepancies between English and Chinese versions of the "The Third Quarter Report of 2025" the Chinese version shall prevail.

SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD

Board of Directors

October 24, 2025